To describe the relative health and economic outcomes associated with different second-line therapeutic approaches to manage glycaemia in older type 2 diabetes patients requiring escalation from metformin monotherapy.
| INTRODUCTION
Type 2 diabetes is the most common metabolic disorder in the older adult population and imposes considerable burden on patient health, life expectancy and associated quality of life. The appropriate management of older patients is imperative, given the rising prevalence of type 2 diabetes and that older patients account for the majority of newly diagnosed cases. 1 Diabetes-related vascular complications, such as cardiovascular disease, visual loss and foot disease, increase the risk of disability significantly. The care of older people with diabetes is also complicated by the presence of comorbidities, frailty and the frequent use of medicines that together pose various management challenges for the clinical team. [1] [2] [3] [4] Recent guidance advocates an individualized approach to glycaemia management, reflecting the physical, psychological and social challenges in providing appropriate care to this patient group. 1, 5, 6 Evidence from randomized controlled trials is emerging as to the feasibility and benefit of treating older patients to individualized glycated haemoglobin (HbA1c) targets. 7 This is complementary to the findings of the key intensive glucose control trials, that were suggestive of clinical benefit from tight glycaemic control in older patients with short duration of diabetes, low HbA1c levels or a low number of comorbidities. 2, 4, 7, 8 There remains a paucity of data, however, on the outcomes of alternative approaches to glycaemic management in the older patient, 1 and a need to establish whether the benefits of tight glycaemic control suggested by existing and recent trials are observed in routine clinical practice. Previously, Morgan et al. addressed the question, "What next after metformin?", with a retrospective evaluation of the outcomes associated with second-line glucose-lowering therapies amongst type 2 diabetes patients of all ages in UK clinical practice. 9 They found that pioglitazone, a thiazolidinedione (TZD), was associated with superior clinical outcomes compared with sulphonylurea (SU) when added to metformin, and that SU monotherapy resulted in the worst outcomes. 9 Prescribing beyond SU therapy in older patients is also justified in view of the unnecessary high risk of hypoglycaemia in this population 10 ; however, whilst this evidence is certainly useful, it does not specifically comment on the utility of managing glycaemia in older patients in terms of superiority of clinical outcomes, or whether alternative therapeutic approaches to glycaemia management represent value for money.
Although SU added to metformin has previously been described as the most cost-effective prescribing alternative after metformin monotherapy failure, 11 there is a requirement to demonstrate the cost-effectiveness of prescribing beyond SU at second-line, particularly amongst older patients. Considering this, the present study sought to provide evidence that can inform the utility, from clinical and cost-effectiveness perspectives, associated with different therapeutic approaches to manage glycaemia in older patients with type 2 diabetes. Given that metformin is the most commonly prescribed first-line glucose-lowering agent in this age group, we conducted the present retrospective observational study, with economic assessment, in older patients failing metformin monotherapy who escalated to second-line therapy. The regimens examined in the study included SU, dipeptidyl peptidase-4 (DPP-4) inhibitors, and TZD-based therapies, as these are advocated in current UK clinical guidelines 12 and were the most commonly prescribed second-line agents in a large UK primary care database: the Clinical Practice Research Datalink (CPRD), 13 formerly the General Practice Research Database (GPRD). The CPRD database was used in the present study as it represents a source of real-world clinical data on elderly patients with type 2 diabetes, a population not typically captured in randomized controlled trials.
| MATERIALS AND METHODS

| Data source
The CPRD database was established in 1987, and contains data for 11.3 million individuals registered with selected general practitioners (GPs) in the UK. 14 The CPRD has been the source of many observational studies, including research on diabetes and antidiabetic therapies. 15, 16 In the present analysis, patient-level data were extracted from the CPRD database to obtain patient demographic and lifestyle information, as well as information on medical diagnoses, 
| Study outcomes
The primary outcomes evaluated included time to first event and total event rates, based on patient follow-up post index date. Time to first event included any diabetes-related complication (termed "any event"; see Table 2 Hazard ratios were used to compare outcome risk for each second-line regimen with SU (the most commonly observed index regimen). Data were reported for "all cases, incident and prevalent", "prevalent cases" and "incident cases", based on patient event history prior to the index date.
| Statistical analyses
| Economic analyses
The health and economic consequences associated with the choice of second-line treatment in older patients were assessed using the CORE Diabetes Model (CDM). 19 Cost-effectiveness was evaluated in Tables S1 and S2. 3 | RESULTS
| Baseline patient characteristics
Based on prescription records within the CPRD database, a total of 514 734 patients were identified as having type 2 diabetes. Of these, a total of 10 484 patients were considered eligible for inclusion in the present study ( Figure S1 in Appendix S1). At baseline, patients had a mean age of 73 years, HbA1c of 8.3%, disease duration of 6 years and body weight of 87 kg. Approximately 56% of the cohort were men, 12% had a history of MACE, and 13% had a history of diabetic retinopathy. After metformin monotherapy failure, the majority of patients (42%) had an SU added to metformin (metformin + SU), or were switched to SU monotherapy (28%). Far fewer patients were escalated (added or switched) to a DPP-4 inhibitor or a TZD-based regimen (20% and 9%, respectively). Baseline characteristics of the cohort are summarized in Table 1 . 
| Time to first event analysis
Hazard ratios for time to first MI, stroke, MACE or any event were not statistically significant for any alternative regimen compared with metformin + SU. Trends in incident and prevalent cases were similar (in patients with and without a history of the complication; Figure 1 and Table S3 in Appendix S1). For all-cause mortality, when compared with metformin + SU, hazard ratios were higher for SU monotherapy (hazard ratios >1; P < .05 in unadjusted and age-and sex- 
| Total event analysis
Over a mean follow-up time of 2.44 years (maximum 7 years), a total of 3279 complications were observed across patients escalating to a second-line regimen ( Table 2 ). The SU monotherapy cohort was asso- In multivariate adjusted analyses, total event rates per 1000
person-years for metformin + DPP-4 inhibitor were significantly lower compared with metformin + SU for MACE (incidence rate ratio 0.61, 95% CI 0.39-0.98; Figure S4 and Table S5 in Appendix S1). In all cases, this was driven by a lower event rate for MI in the metformin + DPP-4 inhibitor group (incidence rate ratio 0.52, 95% CI 0.27-0.99). This finding was significant in the all-case analysis, with a trend towards a hazard ratio <1 in the incident-only and prevalent-only Abbreviations: CHF, congestive heart failure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease; PVD, peripheral vascular disease; SBP, systolic blood pressure.
Treatment-related
1
Any history of an event in the pre-index period. A multivariate analysis of total events, stratified by total patient follow-up time post index date, demonstrated a statistically significant lower total event incidence (incidence rate ratio <1) for metformin + DPP-4 inhibitor compared with metformin + SU for patients with ≥1 (borderline significant), 2 and 3 years follow-up ( Figure S5 in Appendix S1). The incident rates between regimens for MI, stroke and MACE, stratified by follow-up time, were not statistically significant.
| Analysis of HbA1c and weight
Analysis of the secondary outcomes (change in HbA1c and weight from baseline to 12 months) suggested that weight increased overall and for all treatment cohorts except metformin + DPP-4 inhibitor and DPP-4 inhibitor monotherapy, which were associated with significant reductions in weight (−1.21 and −1.06 kg, respectively; P < .001 vs other regimens; Table S4 in Appendix S1). The metformin + SU cohort was 
| Economic analyses
The first economic analysis compared the cost-effectiveness of the most commonly observed dual therapy second-line treatment regimens (Table 3) . In this analysis, metformin + DPP-4 inhibitor was associated with the largest gain in health benefit (QALYs) but at an incremental cost compared with metformin + SU and metformin + TZD. The costs per QALY gained for metformin + DPP-4 inhibitor were £15 343 versus metformin + TZD and £18 680 versus metformin + SU, which are within conventional thresholds for costeffectiveness in the UK of between £20 000 and £30 000 per QALY. The probability that metformin + DPP-4 inhibitor was costeffective at the £30 000 threshold was 57% and 62% compared with metformin +SU and metformin + TZD, respectively. Similar results were observed in a scenario analysis, where the switch to rescue therapy was assumed to occur once baseline HbA1c had returned to baseline values.
The second economic analysis was used to evaluate the costeffectiveness of the prescribing or treatment decision (Table 4) . In this analysis, all second-line regimens were associated with favourable cost-effectiveness ratios: metformin + DPP-4 inhibitor and metformin + SU had similar cost per QALY estimates of £21 318 and £17 640, respectively; and metformin + TZD was cost-saving with QALY gains attributable to its cost and effect profile when compared against itself. The probability that metformin + DPP-4 inhibitor was cost-effective at the £30 000 threshold was 61%, 54% for metformin + SU, and 74% for metformin + TZD. Abbreviations: CHF, congestive heart failure; IHD, ischaemic heart disease; PVD, peripheral vascular disease.
| DISCUSSION
Despite the rising prevalence of type 2 diabetes within an aging population, there is a paucity of clinical and economic data to inform on the utility of therapeutic strategies to manage older patients who have In subgroup analyses, second-line regimens were compared with metformin + SU for: (1) different minimum follow-up periods post index date, to explore the idea that a minimum number of follow-up years are required to observe the effects of different glucoselowering agents on macrovascular event rates, and (2) patients with a history of an event to mimic "high-risk" patients, such as those with a previous MI or stroke. In these analyses, the metformin + DPP-4
inhibitor group was associated with lower time to first event and total event incidence for longer follow-up periods (≥3 years) and a lower total event incidence for MI and MACE when analysing incidence and prevalence cases together (with a trend towards lower incidence when incidence/prevalence groups were analysed separately). In these subgroup analyses, across all regimens, "all" patients tended to have a higher (non-significant) risk compared with strata of increasingly longer follow-up who had a trend towards reduced risk.
This apparent discrepancy may be explained by the non-exhaustive nature of the reported stratified analyses. Data pertaining to stratified duration analyses (≥1-3 years) do not capture patients with follow-up <1 year, and in these patients, rate ratios were similar to the "all" patient data. This may be evidence of a survivorship effect, in that patients with longer observed follow-up tended to have lower event risk across all regimens. Conversely, the data may suggest that a minimum follow-up period is required to observe significant differences in event outcomes across alternative glucose-lowering regimens. In the present study, the only group associated with a statistically significant reduction in event risk as follow-up time increased was the metformin + DPP-4 inhibitor group.
Previous database studies have reported improved clinical outcomes with DPP-4 inhibitor-based regimens, compared with other approaches of glycaemic management for type 2 diabetes. 22 The Abbreviations: CE, cost-effective; k, thousand; RT, rescue therapy. causality between treatment and outcome can be difficult from these types of data. The approach used to minimize the impact of confounding in the present study was to select a homogenous cohort (patients on metformin monotherapy requiring therapy change), and to evaluate primary and secondary outcomes using stratification and statistical adjustment as the principle mechanisms of accounting for the effect of differences in patient type and prescribing choice on study outcomes. As part of this approach, regression models were fitted to the data to estimate within-and between-group differences in outcomes, adjusting for the influence of observed covariates at baseline. It is acknowledged that statistical adjustment for observed covariates within and between strata is unlikely to account for all sources of variation; thus, adjusted estimates are reported with explicit reference to these potential limitations.
There are several strengths and limitations associated with the use of routinely collected data such as those contained in the CPRD database. Given the current lack of randomized controlled trial data informing on the efficacy of second-line therapies in older patients with type 2 diabetes, the greatest strength of the CPRD database in the context of the present study was that it provided informative real-world data on the population of interest. Variables including weight, smoking status and HbA1c were also likely to be well cap- 
